Research shows how 'Mallard' dye fills need for speedFebruary 15, 2013
Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood.
Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.
In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.
The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.
Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.
Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.
"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."
The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.
The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.
University of York
Related Heparin Current Events and Heparin News Articles
Revised guidelines on reducing risk, treatment options for thromboembolic disease in pregnancy
Advice on preventing and treating venous thromboembolism (VTE) during pregnancy, birth and following delivery is outlined in two new revised guidelines published today (13 April) by the Royal College of Obstetricians and Gynaecologists (RCOG) and launched at the RCOG World Congress in Brisbane, Australia.
Common drug is re-engineered to improve surgery outcomes
A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.
Serious risks from common IV devices mean doctors should choose carefully, U-M experts say
Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots.
Trial of bivalirudin during angioplasty reports mixed results
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy.
ASH report: 'Systems-based' hematologist is new way to provide hematology expertise
A report, released today from the American Society of Hematology (ASH) in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today's rapidly changing U.S. health-care system.
Platelet transfusions increase odds of death in some rare blood cell disorders
People hospitalized with certain rare blood cell disorders frequently receive a treatment that is associated with a two- to fivefold increase in death, according to a new study that reviewed hospital records nationwide.
Apixaban in deep vein thrombosis and pulmonary embolism: patients with high BMI benefit considerably
Apixaban (trade name Eliquis) has been approved since July 2014 for acute treatment of adults with deep vein thrombosis or pulmonary embolism.
Combined strategies help patients with adverse heparin reaction before heart surgery
New evidence suggests that therapeutic plasma exchange and appropriate blood testing could help patients who are in urgent need of heart surgery, but have a history of an adverse reaction to the blood thinner heparin.
Some heparin-allergic patients could have urgent heart surgery sooner with combination of appropriate blood screenings and therapeutic plasma exchange
McMaster University researchers have found new evidence that suggests patients with a history of adverse reaction to the blood thinner heparin may be ready for urgent heart surgery sooner with a combination of appropriate blood screenings and therapeutic plasma exchange.
UBC researchers aim to simplify life saving drug
Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by developing a universal antidote.
More Heparin Current Events and Heparin News Articles